Aveanna Healthcare Holdings (AVAH) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

71OpportunityDD: Aug 03, 2026Analyst: 71

paidPrice at analysis date

USD 9.39 (03/08/2026)

domainMkt cap

$2.04B

pie_chartShares

217.76M

candlestick_chart52W

$3.73-$10.32

trending_downShort interest

INFONASDAQHealth Care35500 employeesFounded 2016

Verdict: Favorable Risk/Reward — Value with beat-and-raise momentum

Small-cap home-care platform (mkt cap $2.04B) trading at 13.2x forward P/E after 14 consecutive quarters of operational outperformance. Q1 2026 crushed consensus (+41% EPS surprise), guidance raised twice (revenue $2.63-2.65B, adj. EBITDA $338-342M). Deleveraging path from 3.8x to sub-3x visible; May 2026 debt repricing already saves interest. Rating capped by residual Medicaid rate exposure and ~$1.48B leverage still elevated. Fair value $9.90 implies limited upside (~+5%); asymmetry improves only with Q2 beat + guidance raise on Aug 13.

📊 DIANALITICS RESEARCH INDEX Company & Thesis Assessment Score /100 — updated 2026-08-03

Aveanna Healthcare Holdings (AVAH)

Home Healthcare Services · NASDAQ · Atlanta, GA

"Value-tier operational compounder still carrying leverage; beat-and-raise cadence supports modest re-rating."

14 consecutive beats Guidance raised 2x YTD Leverage 3.5-3.8x Fwd P/E 13.2x Medicaid rate exposure

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value estimate — SotP EV/EBITDA (3 business units)

Fair value base case

USD 9.90

Range: USD 5.00-USD 13.5

Price at analysis date: USD 9.39 (03/08/2026)

Base upside/downside: +5%

Primary method is SotP EV/EBITDA per business unit using peer-derived multiples (ADUS/EHAB/BTSG median 10-11x fwd). Implied blended multiple 10.3x is within ±20% of nominal per-segment range. Cross-check via consolidated forward P/E ($0.75 × 13.5x = $10.13) reconciles within ±3%. Sensitivity: a ±1x change in blended EV/EBITDA moves FV by ~$1.60/sh (16%); ±10% change in FY26E EBITDA moves FV by ~$1.60/sh (16%). Probability-weighted FV = 0.20×$13 + 0.55×$9.75 + 0.25×$5.75 = $9.40, essentially at the current price — indicating the market is pricing AVAH close to a fair expected value with limited asymmetry from here. ⚠️ Not investment advice.

Component	Assumption	USD/share
PDS segment EV (Private Duty Services)	~$2.15B FY26E rev × 13% EBITDA margin = $280M EBITDA × 10.0x EV/EBITDA (in line with ADUS ex-growth premium)	+12.86
HHH segment EV (Home Health & Hospice)	~$320M FY26E rev × 15% EBITDA margin = $48M EBITDA × 10.5x EV/EBITDA (post-acute tailwind)	+2.31
MS segment EV (Medical Solutions)	~$130M FY26E rev × 18% EBITDA margin = $23M EBITDA × 11.0x EV/EBITDA (higher-margin distribution)	+1.16
FCF-driven deleveraging (next 12 mo)	~$50M annualized FCF post debt-repricing / 217.76M shares = discrete equity accretion	+0.23
Less: net debt (projected end-Q2 2026)	$1.48B Q1 gross debt − $40M FCF paydown − ~$40M cash = ~$1.44B net / 217.76M shares	−6.61
FV base case	Arithmetic sum: 12.86 + 2.31 + 1.16 + 0.23 − 6.61	≈ $9.95

Bull

$12.50 – $13.50

Probability: 20%

Q2 beat + third guidance raise (rev $2.68B+, EBITDA $355M+); leverage to sub-3x by year-end; multiple expands to 11.5-12x EV/EBITDA as peers close (ADUS gap). Requires stable Medicaid reimbursement environment.

Base

$9.00 – $10.50

Probability: 55%

In-line Q2, guidance reaffirmed. FY26 lands at guidance midpoint ($2.64B rev, $340M EBITDA); deleveraging on track. Multiple stays near 10x EV/EBITDA; consensus PT $10.30 credible.

Bear

$5.00 – $6.50

Probability: 25%

Medicaid rate cut (state-level or "One Big Beautiful Bill" federal reset), integration issues with Family First, or PDS labor cost surge compress margin to 11%. EBITDA slips to $310M; multiple de-rates to 8x on leverage concern → equity ~$1.0-1.4B.

Methodology: Primary method is SotP EV/EBITDA per business unit using peer-derived multiples (ADUS/EHAB/BTSG median 10-11x fwd). Implied blended multiple 10.3x is within ±20% of nominal per-segment range. Cross-check via consolidated forward P/E ($0.75 × 13.5x = $10.13) reconciles within ±3%. Sensitivity: a ±1x change in blended EV/EBITDA moves FV by ~$1.60/sh (16%); ±10% change in FY26E EBITDA moves FV by ~$1.60/sh (16%). Probability-weighted FV = 0.20×$13 + 0.55×$9.75 + 0.25×$5.75 = $9.40, essentially at the current price — indicating the market is pricing AVAH close to a fair expected value with limited asymmetry from here. ⚠️ Not investment advice. Not investment advice.

⚠️ Methodology note: AVAH is a leveraged services roll-up (post-M&A); primary valuation is EV/EBITDA per business unit with forward multiples benchmarked to home-care peers (ADUS, EHAB, BTSG). Free-cash-flow deleveraging is modeled as a discrete FV contributor, not blended into the multiple. Family First Homecare acquisition (closed June 2, 2026) is already fully baked into revised FY26 guidance used in the base case.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~5-6%

Moderate short interest for a name that has doubled off 2025 lows ($3.73). Days-to-cover ~3-4 given ~2.3M avg daily volume. Not squeeze-prone.

🟡 Share dilution (1Y)

+2-3%

From ~213M to 217.76M shares outstanding (equity-linked comp + minor issuance for Family First deal). Contained.

🔴 Buyback

No repurchase program active. Capital allocation priorities: deleveraging first (net debt/EBITDA to sub-3x), then bolt-on M&A (Family First playbook).

Short Interest — context

AVAH — ~5-6%

~5-6%

SI in the 5-15% range signals modest skepticism (typically Medicaid rate risk + leverage worry) but is not a squeeze setup. Insider transactions (Form 4, last 12 months): no material sales >$500K disclosed publicly; no CFO/CEO change; no active class action or short-seller report as of report date (only historical 2023 data breach and 2022 Pomerantz investigation, both resolved).

$Financial analysis — FY 2025-2026E

Revenue (TTM)

$2.52B

+20.5% YoY

Adj. EBITDA (FY26E)

$340M

+22-25% YoY, guidance raised 2x

Net income (TTM)

$261M

Q4 2025 boosted by $139M tax benefit (deferred asset)

Net debt (Q1 2026)

$1.44B

3.8x EBITDA → target sub-3x by end-2026

Item	FY2023	FY2024	FY2025	FY2026E (guidance mid)
Revenue ($M)	1,873	2,020	2,207	2,640
YoY growth %	+3%	+8%	+9%	+19.6%
Adj. EBITDA ($M)	159	207	270	340
Adj. EBITDA margin %	8.5%	10.2%	12.2%	~12.9%
Net income ($M)	−201	−34	228	~165
Diluted EPS ($)	−1.06	−0.18	1.08	~0.75
Net debt ($M)	1,588	1,505	1,485	~1,380 (target)
Leverage x EBITDA	10.0x	7.3x	5.5x	~4.1x (targeting sub-3.0x mid-2027)

Sources: Q1 2026 press release, TIKR filings, FY2025 10-K. FY26E numbers are guidance midpoints raised twice YTD (post-Q1 May 14 and post-Family First close June 2). Q4 2025 net income includes ~$139M deferred tax asset recognition (one-time).

Quarterly dynamics — last 5 quarters (segment-level trend)
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	559.0	589.6	621.9	662.5	647.9
YoY revenue growth %	+7%	+9%	+13%	+15%	+15.9%
Adj. EBITDA ($M)	67.4	86.1	71.0	77.5	84.4
Non-GAAP EPS ($)	0.11	0.18	0.15	0.17	0.18
Cash + revolver headroom ($M)	~250	~270	~290	~310	~340

Financial position and sustainability

FY26E revenue growth vs guidance

+19.6%

Adj. EBITDA margin trend (FY23→FY26E)

8.5% → 12.9%

Leverage reduction path (target: sub-3x)

4.1x FY26E

Analyst PT vs current (avg $10.30)

+9.7% upside

account_tree

Business model — Diversified home-care platform for medically complex patients

Home-care roll-up leveraging preferred-payor economics and value-based care shift

Aveanna is the largest US private-pay pediatric home-care provider, delivering care to ~50,000 patients through ~35,500 caregivers across 200+ locations. Business model is fee-for-service on Medicaid/Medicare/commercial, but the strategic thrust is preferred-payor agreements — negotiated multi-year contracts (like the ones with Anthem-related plans) that lock in higher reimbursement in exchange for value delivered (fewer hospitalizations, better outcomes). The June 2026 Family First Homecare acquisition adds Florida density and ~$60M annualized revenue. Long-term thesis rests on the arbitrage between hospital/nursing-home cost per patient day and home-based care cost — a 60-70% savings that payors are increasingly willing to route toward providers with proven outcomes.

Private Duty Services (PDS) ~$2.15B FY26E (~82% rev) 🟢 ramping Pediatric nursing for medically complex kids on Medicaid waivers. Volume +10.7% Q1 2026, 12.1M hours of care. Preferred-payor deals lifting reimbursement. Main risk: state Medicaid rate resets. Home Health & Hospice (HHH) ~$320M FY26E (~12% rev) 🟢 ramping Medicare-focused post-acute. Family First adds Florida hospice scale. Structurally higher margin (~15% EBITDA) than PDS. Growth benefits from CMS reimbursement stability and hospice demand demographics. Medical Solutions (MS) ~$130M FY26E (~5% rev) 🟡 stable Enteral nutrition and specialty medical products distribution. Smallest but highest-margin segment (~18% EBITDA). Provides cross-sell into PDS/HHH patient base; stable single-digit growth.

gavel

Legal, regulatory and risk analysis

Medicaid reimbursement rate cuts

High

PDS revenue (~82% of total) depends heavily on state Medicaid waiver rates. Federal "One Big Beautiful Bill" or state-level fiscal pressure could trigger reimbursement resets. Historical precedent (2019-2021 rate cuts) hit margins sharply.

Leverage 3.5-3.8x EBITDA

Moderate

Net debt $1.44B on projected FY26E EBITDA $340M = 4.1x. Above home-care peer average (2-2.5x). May 2026 debt repricing improved interest cost, but a growth/margin miss + higher-for-longer rates could delay the sub-3x deleveraging target.

Caregiver labor cost inflation

Moderate

Pediatric nursing requires specialized RNs/LPNs in a persistent labor shortage. Wage increases must be passed through preferred-payor rate resets — timing lag pressures gross margin. Q1 GM was stable but Q2-Q3 seasonal wage bump is inherent risk.

M&A integration (Family First)

Moderate

Family First Homecare closed June 2, 2026. Guidance raise assumes clean integration. History of AVAH acquisitions is mixed (2021-2022 rollups saddled goodwill and leverage). Investors will watch Q2 for margin pull-through.

Small-cap liquidity / beta 1.89

Moderate

Market cap $2.04B with 2.3M avg daily volume. Beta 1.89 signals amplified moves in risk-off tape. Small-cap flows swings (Russell 2000 rebalances, sector rotation) can move AVAH ±5-10% intraday independent of fundamentals.

14 consecutive quarter beats

Positive

Management has delivered a "beat and raise" cadence for 14 straight quarters (Stephens characterization). Credibility of guidance is high; disappointment risk on Aug 13 earnings is asymmetric downside because the base rate of positive surprise is very high.

Value-based care structural tailwind

Positive

Payors (Anthem, UnitedHealth, Medicare Advantage plans) are actively steering complex-care patients toward preferred home-care providers with data on outcomes. AVAH is one of the few pediatric platforms with the scale and IT to bid on these contracts.

Historical data breach / HIPAA — resolved

Low

2023 breach and 2024-2025 class actions resulted in a HIPAA settlement (~$425K) and civil settlements. No new active shareholder class action or SEC investigation as of report date. Cyber posture remediated; residual reputational tail is contained.

article

SWOT analysis

Strengths

+14 consecutive quarters of EPS beat & raised guidance twice in 2026
+Largest US pediatric home-care platform (~50K patients, 35.5K caregivers)
+Preferred-payor strategy delivering rate improvements independent of Medicaid
+EBITDA margin expansion from 8.5% (FY23) to 12.9% (FY26E) — 440 bps
+Successful debt repricing May 2026 lowers interest cost

Weaknesses

−Leverage 3.5-3.8x EBITDA; above peer median (~2-2.5x)
−Heavy Medicaid concentration in PDS (~82% of revenue) exposes to rate resets
−Caregiver labor cost inflation persistent — wage-to-rate lag squeezes GM
−No buyback program; capital allocation locked to deleveraging
−Historical net losses through FY24; positive earnings only recent

Opportunities

→Q2 2026 earnings Aug 13 — potential 15th consecutive beat + guidance raise
→Multiple compression vs ADUS/BTSG as leverage normalizes (~200 bps re-rate)
→Bolt-on M&A pipeline (Family First playbook) in fragmented pediatric home-care
→Value-based care contracts expansion beyond current Anthem-related payors
→Demographics: aging population + push out of institutional care = 8-10% sector tailwind

Threats

!"One Big Beautiful Bill" or state Medicaid reset — direct EBITDA hit possible
!Competing large-cap payor-owned home-health (UnitedHealth-Amedisys, Humana-Kindred at Home)
!Nursing labor market tightening beyond current inflation assumption
!CMS Home Health payment rule changes (annual notice) could clip HHH growth
!Small-cap correction / risk-off rotation (beta 1.89 amplifies)

article

Summary by assessment area

🟡 Financial risk — Moderate

Leverage 4.1x FY26E vs sub-3x target — 12-18 months of visible deleveraging
EBITDA growth 25%+ funds interest and paydown; no covenant risk flagged
Positive FCF and improved interest cost post May 2026 repricing

🟢 Operational risk — Low-Moderate

14 consecutive quarterly EPS beats — highest-conviction guidance credibility in sector
Preferred-payor volumes ramping; Family First integration in flight but small deal size (~$60M rev)
Caregiver labor cost inflation still the main margin swing variable Q-by-Q

🟡 Regulatory risk — Moderate-High

Medicaid rate exposure structurally elevated (~82% PDS revenue)
Federal "Big Beautiful Bill" and state fiscal pressure = binary risk in 2027 budget cycles
Data breach class actions historically resolved; no new active litigation

2026-08-13 earnings

Q2 2026 Earnings Release (pre-market)

short-term Impact: High Direction: Binary

15th consecutive quarter beat + potential third guidance raise. Base rate of positive surprise very high, but stock has already re-rated from $3.73 lows — asymmetric downside risk if just an in-line print.

2026-09-30 ma

Family First Homecare — first full quarter contribution

short-term Impact: Medium Direction: Bullish

Q3 2026 will be the first quarter with Family First fully consolidated. Guidance raise ($328M → $340M EBITDA) reflects deal accretion; execution proof-point.

2026-10-15 regulatory

State Medicaid budget cycles (Oct-Dec 2026)

medium-term Impact: High Direction: Binary

Key AVAH states (TX, CA, FL, PA) enter FY2027 budget prep in Q4. Any rate cut proposals for pediatric home-nursing waivers hits PDS revenue directly. Watchlist state.

2026-11-01 regulatory

CMS Home Health 2027 Payment Rule — final release

medium-term Impact: Medium Direction: Neutral

Annual Medicare rulemaking affects HHH segment (~12% revenue). Historically 0-2% adjustments; watch for behavioral offset methodology changes that could clip base rate.

2026-11-05 earnings

Q3 2026 Earnings — first full Family First quarter

medium-term Impact: High Direction: Binary

First Q3 with clean Family First contribution. FY26 guidance likely reaffirmed or raised for the fourth time. Leverage trajectory update key for deleveraging thesis.

2027-02-25 guidance

FY2027 initial guidance (with Q4 2026 print)

medium-term Impact: High Direction: Binary

First look at 2027 growth algorithm. Base case: 12-15% revenue growth, EBITDA $380-400M. Bull case: continued preferred-payor traction pushes above range and confirms sub-3x leverage by mid-2027.

2027-05-15 capital_markets

Net-debt/EBITDA crosses sub-3.0x target

long-term Impact: High Direction: Bullish

The re-rating catalyst. Sub-3x leverage removes the primary discount vs ADUS/BTSG. Historical precedent: peers re-rated 150-250 bps EV/EBITDA on similar deleveraging arcs.

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole", "en": "Verdict: Favorable Risk/Reward"}, "verdict_text": {"it": "AVAH e' un small-cap home-care con 14 trimestri consecutivi di beat, guidance rialzata 2 volte nel 2026 e fwd P/E 13.2x. Fair value $9.90 con upside base ~+5% e catalyst-driven upside al Q2 del 13 agosto.", "en": "AVAH is a home-care small-cap with 14 consecutive beats, guidance raised twice in 2026 and forward P/E 13.2x. Fair value $9.90 with ~+5% base upside and catalyst-driven upside at Aug 13 Q2 earnings."}, "bull_points": [ {"it": "14 trimestri consecutivi di beat con guidance rialzata 2 volte nel 2026 (rev $2.63-2.65B, EBITDA $338-342M).", "en": "14 consecutive quarterly beats with guidance raised twice in 2026 (rev $2.63-2.65B, EBITDA $338-342M)."}, {"it": "Deleveraging visibile da 3.8x a sub-3x entro mid-2027 dopo repricing debito maggio 2026.", "en": "Visible deleveraging path from 3.8x to sub-3x by mid-2027 after May 2026 debt repricing."}, {"it": "Sconto valutativo vs ADUS/BTSG (fwd P/E 13.2x vs 16-20x peer) si comprime quando la leva normalizza.", "en": "Valuation discount vs ADUS/BTSG (fwd P/E 13.2x vs 16-20x peers) compresses as leverage normalizes."} ], "bear_points": [ {"it": "Esposizione Medicaid ~82% del revenue: rate cut statali o federali (Big Beautiful Bill) colpiscono direttamente EBITDA.", "en": "Medicaid exposure ~82% of revenue: state or federal rate cuts (Big Beautiful Bill) hit EBITDA directly."}, {"it": "Leva ancora elevata a 3.5-3.8x EBITDA vs peer 2-2.5x; recessione labor + rate = squeeze margine.", "en": "Leverage still elevated at 3.5-3.8x EBITDA vs peer 2-2.5x; labor recession + rates = margin squeeze."}, {"it": "Prezzo probabilita'-pesata $9.40 e' sotto FV base $9.90: upside limitato senza nuovi catalyst.", "en": "Probability-weighted FV $9.40 is below $9.90 base: limited upside without new catalysts."} ], "risks": [ {"it": "Q2 earnings del 13 agosto: base rate di sorpresa positiva alta, downside asimmetrico su in-line print.", "en": "Aug 13 Q2 earnings: high base rate of positive surprise, asymmetric downside on in-line print."}, {"it": "Medicaid state/federal rate resets nel ciclo budget Q4 2026-2027.", "en": "Medicaid state/federal rate resets in Q4 2026-2027 budget cycles."}, {"it": "Integrazione Family First e caregiver labor cost inflation sul margine Q-by-Q.", "en": "Family First integration and caregiver labor cost inflation on Q-by-Q margins."} ] }

Sources & Disclaimer

Sources: Aveanna IR (Q1 2026 press release, May 14 2026), Google Finance (analyst PT table, updated 2026-07-14), StockAnalysis.com (Aug 1 refresh), Stocktwits, Yahoo Finance, Seeking Alpha, Tikr blog, Simply Wall St, RBC/Barclays/Stephens/Truist/BMO/Jefferies notes summaries. Market data — last verified close 2026-07-31: AVAH $9.39 (−3.10% vs $9.69 prev close), market cap ~$2.04B, 52W: $3.73–$10.32, 217.76M shares outstanding. Short interest: ~5-6% (moderate). Earnings date next: Aug 13, 2026 (pre-market). Family First Homecare deal closed June 2, 2026. This document is for informational purposes only and does not constitute financial or investment advice.